Degree and PhD in Medicine, specialist in Neurosurgery, and Global Executive MBA (IESE).
He founded the "Innovation and entrepreneurship program" at the Barcelona Medical Association (CoMB), where he has been coaching entrepeneurs and he has founded and directed the Healthcare Investment Forums since 2009.
He has been an entrepreneur himself in the healthcare space and raised capital from investors.
Deeply involved in the innovation ecosystem, he is a member and advisor of many healthcare innovation organizations such as Biocat (Board of Trustees), CIMTI, BarcelonaActiva Mentoring Program, Generalitat de Catalunya-CASOST and HEALTHIO among others.
Author of numerous books in the field of innovation, venture capital and healthcare, such as "Innovation and Entrepreneurship in Healthcare", published internationally. In the academic space, he has been a teacher in several business schools about healthcare innovation and venture capital.
He remains as the Director of Healthequity, SCR, a venture capital fund focused in early-stage companies in the healthcare sector, where he led the investment strategy and transaction processes of the different portfolio companies. Member of the Board of Directors of different life-sciences companies including Healthequity's investments: Versantis, n-life Therapeutics and Minoryx Therapeutics.
He has founded the managing company Invivo Capital Partners together with Albert Ferrer.
Graduated in Business Administration and MBA from ESADE, Master CEMS (Community of European Management Schools) in Management from HEC – Hautes Études Commerciales (París) and Chartered Financial Analyst (CFA).
He has been involved in the Spanish VC industry for the past 15 years through Grupo Financiero Riva y García with a focus on high-growth, early stage, technology centered investments.
Previously, he led the finance department of an internet start-up. He also worked in the marketing department of multinational corporations.
Specialist in corporate and asset valuation, transaction structuring and execution. Experienced in different transactions: capital increases, mezzanine loans, company acquisitions, trade sales, asset sales and international transactions. He has been a member of the Board of Directors of various companies such as Wecare-u and Scytl.
He remains as the Director of Healthequity, SCR, a venture capital fund focused in early-stage companies in the healthcare sector. He led the investment strategy and transaction processes of the different portfolio companies. He has been a member of the Board of Directors of different life-sciences companies and of Healthequity's investments: Sanifit, Peptomyc and GlyCardial Diagnostics.
He has founded the managing company Invivo Capital Partners together with Lluís Pareras.
Bachelor of Science in Biotechnology from the Autonomous University of Barcelona (UAB), PhD in Genetics from the University of Barcelona (UB) and Master’s Degree in Management of Business Aspects of Science and Technology from Barcelona School of Management (UPF).
More than 5 years of research in Developmental Genetics and Control of Cell Growth at the Institute for Research in Biomedicine (IRB) in Barcelona, being the author of several scientific publications in peer-reviewed journals.
3 years of experience as a Project Manager in drug development at the biotech company Advancell, S.A, and more than 2 years of experience as a Portfolio Manager and Business Development at the Knowledge Transfer and Innovation unit at Vall d'Hebron Institute of Research in Barcelona (VHIR).
She also created the working group "ASBTEC and business" through the non-profit Association of Biotechnologists of Catalonia (ASBTEC), to foster relations between scientific research and biotech companies.
She usually collaborates with different entities of the health innovation ecosystem as a start-up mentor and evaluator (COMB, EIT Health, Ship2b, Fundació Bosch i Gimpera, among others) and as a teacher in the “Project management for pharma development process” postgraduate course at University of Barcelona (UB).
Since May 2016, she has been working as Investment analyst at Healthequity, SCR, a venture capital fund focused in early-stage companies in the healthcare sector.
Bachelor of Science in Biotechnology from the Autonomous University of Barcelona (UAB), PhD in Biotechnology from the University of Barcelona (UB) and a Postgraduate course in Innovation Management (UAB).
5 years of experience in research in gene therapy applications in the cancer field that led to publications in peer-reviewed journals and collaborations with biotech companies. She has more than 2 years of experience as a Project Manager in the Knowledge Transfer and Innovation Unit at the Research Institute of the Vall d'Hebron Hospital (VHIR) in Barcelona.
She is an active member in the EIT Health Alumni Network, after her participation in the EIT Health Innovation & Business Creation Summer School, in 2016, co-organized by the Trinity College in Dublin and IESE business school. She usually collaborates with different entities of the health innovation ecosystem as a start-up mentor and evaluator (COMB, EIT Health, Ship2b, Imagine IF!, FIPSE and CIMTI, among others).
Since January 2018, she works as investment analyst in Healthequity SCR, a venture capital fund focused in early-stage companies in the healthcare sector.